Our study also supports the necessity of leveraging genetic models to validate drug targets when possible and suggests that the overall role of IL-23/IL-17 axis in NASH may need to be re-evaluated. The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatohepatitis.